Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Publication
, Journal Article
Hicks, JK; Swen, JJ; Thorn, CF; Sangkuhl, K; Kharasch, ED; Ellingrod, VL; Skaar, TC; Müller, DJ; Gaedigk, A; Stingl, JC ...
Published in: Clin Pharmacol Ther
May 2013
Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
May 2013
Volume
93
Issue
5
Start / End Page
402 / 408
Location
United States
Related Subject Headings
- Polymorphism, Genetic
- Pharmacology & Pharmacy
- Pharmacogenetics
- Mental Disorders
- Humans
- Genotype
- Dose-Response Relationship, Drug
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 CYP2C19
- Aryl Hydrocarbon Hydroxylases
Citation
APA
Chicago
ICMJE
MLA
NLM
Hicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., … Clinical Pharmacogenetics Implementation Consortium, . (2013). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther, 93(5), 402–408. https://doi.org/10.1038/clpt.2013.2
Hicks, J. K., J. J. Swen, C. F. Thorn, K. Sangkuhl, E. D. Kharasch, V. L. Ellingrod, T. C. Skaar, et al. “Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.” Clin Pharmacol Ther 93, no. 5 (May 2013): 402–8. https://doi.org/10.1038/clpt.2013.2.
Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013 May;93(5):402–8.
Hicks, J. K., et al. “Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.” Clin Pharmacol Ther, vol. 93, no. 5, May 2013, pp. 402–08. Pubmed, doi:10.1038/clpt.2013.2.
Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, Stingl JC, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013 May;93(5):402–408.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
May 2013
Volume
93
Issue
5
Start / End Page
402 / 408
Location
United States
Related Subject Headings
- Polymorphism, Genetic
- Pharmacology & Pharmacy
- Pharmacogenetics
- Mental Disorders
- Humans
- Genotype
- Dose-Response Relationship, Drug
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 CYP2C19
- Aryl Hydrocarbon Hydroxylases